Instem, a leading provider of early drug development software solutions, announced today that Mitsubishi Chemical Medience Corporation (MCM) has purchased the Provantis preclinical software solution.
“Increasingly Japanese preclinical software organizations such as MCM are performing FDA regulated studies and they are demanding solutions that meet FDA regulatory requirements.”
Following an extensive competitive evaluation MCM decided to replace its existing data collection systems with the fully integrated Provantis solution to manage Preclinical study processes at their research facilities in Kashima and Kumamoto, Japan.
MCM is one of Japan’s largest CROs. They have purchased a wide range of Provantis modules for over 200 users across the 2 sites, including General Toxicology, Clinical Pathology, Pathology, Reproductive Toxicology and Instem’s unique reporting solution – Protocol & Report Assembly.
MCM has also purchased a range of Professional Services to enable them to get quickly up to speed with the Provantis solution and Instem will be working hand in hand with their Japanese distributor CTCLS to ensure that MCM get quick return from their investment in Provantis. CTCLS is one of Japan’s leading providers of integrated R&D support systems for the life sciences and they support Instem solutions through their full service office in Tokyo.
Provantis was chosen after a detailed competitive evaluation and will replace 2 separate systems that are currently in place at MCM.
Dr. Hideaki Hiratsuka, General Manager of MCM’s Safety Assessment Department commented “As part of our company’s expansion plans and our drive to reduce operational costs and further streamline our processes we were looking for a unified system that we could deploy at multiple locations. We were extremely impressed with the capabilities of the Provantis solution.”